share:
Mapping Performance Variations to See How Lithium-Metal Batteries Fail
Using high-energy x-rays, scientists probed different points across a high-energy-density lithium-metal battery of interest for long-range electric vehicles and used the data to identify the main failure mechanism
April 19, 2021
Brookhaven Lab chemist and Stony Brook University (SBU) professor Peter Khalifah (middle) with SBU graduate students Zhuo Li (left) and Gerard Mattei (right) holding a pouch cell battery attached to a frame used for synchrotron x-ray studies. Note: This photo was taken prior to current COVID-19 social distancing guidelines.
UPTON, NY Scientists have identified the primary cause of failure in a state-of-the-art lithium-metal battery, of interest for long-range electric vehicles. Using high-energy x-rays, they followed the cycling-induced changes at thousands of different points across the battery and mapped the variations in performance. At each point, they used the x-ray data
Mapping performance variations to see how lithium-metal batteries fail eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
February 4, 2021
4 min read
Iwao Ojima, distinguished professor in the Department of Chemistry at Stony Brook University, has been elected as a fellow of the European Academy of Sciences (EurASc). He will be honored at the induction ceremony of new members at EurASc’s Annual Symposium and Ceremony of Awards event this April at the Sorbonne University in Paris, France, which will be held virtually due to the COVID-19 pandemic.
Distinguished Professor Iwao Ojima
Throughout his research career, Dr. Ojima has had numerous ties to the European scientific community. He was first recognized by European chemistry communities in organometallic chemistry, catalysis and fluorine chemistry, prior to joining the faculty at Stony Brook. He has held two sabbaticals at universities in Lyon and Paris, and his inventions on natural product-based anticancer agents were licensed to both French and Italian pharmaceutical companies. Over the years, Dr. Ojima has had a good number of French, Italian